Benefit With Cemiplimab in Patients With mCSCC

December 18, 2018
Danny Rischin, MD, MBBS, FRACP

Danny Rischin, MD, MBBS, FRACP, shares his insights on cemiplimab as a treatment for patients with metastatic cutaneous squamous cell carcinoma.

Danny Rischin, MD, MBBS, FRACP, director, division of cancer medicine, and head, department of medical oncology, Peter MacCallum Cancer Centre, Melbourne, Australia, shares his insights on cemiplimab (Libtayo) as a treatment for patients with metastatic cutaneous squamous cell carcinoma (mCSCC).